Akorn Pays Out $7.9m In Medicare Fraudulent Billing Case
The Whistleblower Behind The Case Will Receive $946,000 From The Settlement
Akorn has agreed to pay out $7.9m to settle allegations that it deliberately sold three generic drugs as prescription-only when they should have been classed as over-the-counter, in a deal with the US Department of Justice. The mislabeling led Medicare Part D to pay out for the drugs for around a year despite the products not being eligible for Medicare coverage.
You may also be interested in...
Fresenius Kabi is looking to make headway into biosimilars but saw its progress limited by COVID-19 in Q2. Management gave an update on the company’s endeavors during the Q2 earnings call, including key tender victories.
Akorn and its subsidiaries in the US have gone ahead with a Chapter 11 bankruptcy filing, paving the way for an in-court sale of the business and bringing the curtain down for now on the story of one of the hottest generic injectable properties of the last decade.
Akorn’s second-quarter results show a drop in sales despite the launch of three new products. The company expects a $10m increase in FDA compliance and data-integrity assessment expenditures because of a warning letter issued over its Somerset manufacturing facility.